Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid and Melphalan in Untreated Multiple Myeloma
NCT00305812Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 2006
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Incidence of dose-limiting toxicity. Started Mar 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00305812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305812.